Ribon Therapeutics

Pioneering Therapeutics Targeting Cellular Stress Pathways

[Ribon Therapeutics @RibonTx]

We are pioneering the development of 1st-in-class therapeutics targeting enzyme families activated under cellular stress conditions. Learn more about us, and our recent financing, on our new website: https://t.co/ytlPZQawZ6

[Ribon Therapeutics @RibonTx]

We are pleased to announce that Boehringer Ingelheim has agreed to acquire our pre-clinical CD38 program, which Ribon developed from target and lead discovery through lead optimization using our proprietary BEACON+ platform. Read more here: https://t.co/9CHKw8LkeV

#CD38 #biotech

[Ribon Therapeutics @RibonTx]

The Ribon team looks forward to a productive time at the upcoming Citi and Morgan Stanley healthcare conferences. We hope to see you there!

#biotech #leadership

[Ribon Therapeutics @RibonTx]

We are pleased to share new preclinical data presented at the European Respiratory Society International Congress 2022 demonstrating the potential of RBN-3143 as a PARP14 inhibitor across a range of inflammatory models. Read more here: https://t.co/o135MmD6ic

#PARP14 #biotech

[Ribon Therapeutics @RibonTx]

Check out our recent publication in ImmunoHorizons highlighting the potential of PARP14 inhibition to attenuate allergic lung inflammation. To read more about this and our other exciting scientific publications and presentations, click here: https://t.co/Rk2fjjRY6k

#biotech

[Ribon Therapeutics @RibonTx]

This #Juneteenth, join us in reflection and celebration of Black culture, heritage and freedom. At Ribon, we strive to make a positive impact in our communities and that starts with each of us!

[Ribon Therapeutics @RibonTx]

We are thrilled to welcome Gary Sutton as our new Chief Business Officer. Gary brings over 18 years of experience in the BioPharma Industry and will be an invaluable member of our team. Read more about our management team here: https://t.co/ExiZAU4d2f

#biotech #leadership

[Ribon Therapeutics @RibonTx]

Join us in celebrating Pride Month this June! At Ribon, we are committed to not only fostering a diverse and inclusive workplace, but also a diverse and inclusive world. Our unique differences are what make us strong.

#PrideMonth #HappyPride

[Ribon Therapeutics @RibonTx]

We are pleased to receive additional financing from our partner, @K2HVenture, as we advance clinical development of RBN-2397 and RBN-3143 and evaluate multiple preclinical programs leveraging stress support pathway biology.

#biotech

[Ribon Therapeutics @RibonTx]

Yesterday, members of our team presented clinical and preclinical data for RBN-2397, our lead program for oncology, at the @AACR 2022 Annual Meeting. Read more here: https://t.co/rl482UWtbN

#biotech #oncology

[Ribon Therapeutics @RibonTx]

We are pleased to initiate our Phase 1b/2 study of RBN-2397 in combination with pembrolizumab in patients with squamous cell carcinoma of the lung. RBN-2397 is a PARP7 inhibitor being evaluated for the treatment of cancer. Read more here: https://t.co/bFuPkKZdeA

#oncology

[Ribon Therapeutics @RibonTx]

Today we announced the initiation of our Phase 1 study of RBN-3143. This study marks our second first-in-class program in the clinic and our first for the treatment of inflammatory disease. Read more here: https://t.co/icZxuCpUc3

#biotech #leadership

[Ribon Therapeutics @RibonTx]

We are thrilled to welcome Prakash Raman, Ph.D., as our new President and CEO. Dr. Raman joins our team during an exciting time of growth and execution. Read more here: https://t.co/fJdq82Ygff

#biotech #leadership

[Ribon Therapeutics @RibonTx]

ICYMI, check out this article written by our CSO, Heike Keilhack, as she shares her unique insights on the many hats she wears in her crucial role at Ribon. Read more here: https://t.co/7d3R7yUuYH

#biotech #leadership

[Ribon Therapeutics @RibonTx]

Thank you to Healthcare Businesswomen's Association New England Region for last week’s fireside chat discussion with our CEO, Vicky Richon. We support HBA’s mission to further the advancement and impact of women in the business of healthcare. Learn more: https://t.co/DB7llsjL5n

[Ribon Therapeutics @RibonTx]

The Ribon team is thrilled to be participating at the Piper Sandler 33rd Annual Virtual Healthcare Conference next week. We hope to see you there!
#biotech

[Ribon Therapeutics @RibonTx]

We’d like to thank @Biotech2050pod for hosting our Chief Scientific Officer, Heike Keilhack, on this week’s podcast. Use the below link to hear more about our incredible science from one of our own!
Listen here: https://t.co/6HiksiVt9d

#biotech #oncology #inflammation

[Biotech2050 Podcast @Biotech2050Pod]

From bench to bedside, join our #inspiring conversation with Heike Keilhack, CSO, at @RibonTx. They are pursuing cutting-edge approaches for #cancer and #inflammatory indications by targeting the #cellular #stress pathways.

https://t.co/y4OOLcgglK
#biotech #WomenInSTEM #startup

[Ribon Therapeutics @RibonTx]

Members of our management team are looking forward to a productive time this week at the SVB Leerink Biopharma Private Company Connect. We hope to see you there!
#biotech

[Ribon Therapeutics @RibonTx]

We’re thrilled to be named a 2021 #Fierce15 Winner by @FierceBiotech! The team at Ribon is dedicated to driving our innovative pipeline of therapeutics targeting stress support pathways for patients with #cancer and #inflammatory diseases. Learn more: https://t.co/NbE0x4k3EI

[Ribon Therapeutics @RibonTx]

We’re pleased to announce the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer. Both have been integral to advancing our novel therapeutics. Read more: https://t.co/wVblfgNW4t
#Biotech #Leadership

[Ribon Therapeutics @RibonTx]

Our paper, published last month in Cancer Cell and highlighting pre-clinical & MOA data for RBN-2397, our small molecule inhibitor of PARP7, was recognized by Cancer Discovery & captured in its Research Watch section. For the abstract: https://t.co/znujx10YG8 #oncology @CD_AACR